| payload |
{"created_at":"2026-04-11T03:10:51.104 {"created_at":"2026-04-11T03:10:51.104915+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:727efeddc118df9a","evidence_event_ids":["evt_c70f861d6171"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000008.txt","as_of":"2026-04-11T03:10:51.104915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000008.txt","company":"UNITED THERAPEUTICS Corp","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000008.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_59ccb28027b838d1","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000008.txt","content_type":"text/plain","enriched_at":"2026-04-11T05:49:38.458543+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000008.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000008.txt","source_event_id":"evt_c70f861d6171","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"3ac44473b0486808","kind":"sec_filing","published_at":"20260410","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-10","2026-04-09","2025-10-31","2026-04-09","2023-03-15","2027-03-15"],"entities":[{"asset_class":"equity","name":"UNITED THERAPEUTICS Corp","relevance":"high","symbol":"UTHR","type":"issuer"},{"asset_class":"person","name":"EDGEMOND JAMES","relevance":"high","symbol":"","type":"reporting_person"},{"asset_class":"person","name":"James Edgemond","relevance":"high","symbol":"","type":"reporting_person_alias"}],"event_type":"listing","information_gaps":["The extracted text is truncated at the end (ends with 'The price repor'), so the full set of transactions/rows and totals may be incomplete.","The filing type is identified as Form 4, but the specific transaction counts (e.g., total shares bought/sold) are not fully summarized in the provided text; only individual row fragments and price ranges are shown.","The signal indicates 'filed 4' but does not provide a prior known state to compare what changed vs earlier filings; therefore, 'delta' vs prior state cannot be determined from the provided content alone."],"key_facts":["SEC filing is Form 4 for UNITED THERAPEUTICS Corp (issuer CI K 0001082554; company CI K 0001636178 shown for accession header).","Filed as of date: 2026-04-10; conformed period of report: 2026-04-09.","Reporting person: EDGEMOND JAMES; listed role: CFO AND TREASURER.","The filing includes transactions in Common Stock and Stock Option.","The filing states the exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered on October 31, 2025.","The filing states the transaction was executed in multiple trades with prices ranging from $574.18 to $575.16 (weighted average price shown as $574.18\u2013$575.16 range; weighted average price referenced in text).","The filing further includes multiple price ranges in subsequent repeated blocks (e.g., $575.18\u2013$576.17, $576.18\u2013$577.14, $577.19\u2013$578.15, $578.22\u2013$579.18, $579.24\u2013$580.23, $580.24\u2013$581.21, $581.25\u2013$581.37), each with a statement that the price reported reflects the weighted average price.","The filing includes an undertaking to provide full information regarding the number of shares and prices upon request to the SEC staff, the issuer, or a security holder."],"numeric_claims":[{"label":"Option exercise price (as shown)","value":"135.42"},{"label":"Common stock transaction price (weighted average references)","value":"574.18 to 575.16 (and other ranges listed)"}],"primary_claim":"Form 4 for United Therapeutics was filed on 2026-04-10 (covering period ended 2026-04-09) reporting stock option exercise and subsequent sale of common shares by James Edgemond under a Rule 10b5-1 plan dated 2025-10-31.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"United Therapeutics (UTHR) filed a Form 4 on 2026-04-10 covering transactions by reporting person James Edgemond (CFO and Treasurer) with common stock and stock options. The filing states the transactions were executed under a Rule 10b5-1 trading plan entered on 2025-10-31.","topics":["SEC Form 4","insider trading","Rule 10b5-1 trading plan","stock option exercise","common stock sale"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 UNITED THERAPEUTICS Corp \u00b7 Filed 20260410","ticker":"UTHR","tickers":["UTHR"],"title":"UTHR filed 4","url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000008.txt"}}... |